Endocrine Abstracts (2013) 32 P75 | DOI: 10.1530/endoabs.32.P75

Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single-dose of denosumab: a pilot study

Stylianos Mandanas, Konstantinos Toulis, Lemonia Mathiopoulou, Efterpi Margaritidou, Konstantinos Georgopoulos, Maria Boudina, Alexandra Chrisoulidou & Kalliopi Pazaitou-Panayiotou


Theagenio Cancer Hospital, Thessaloniki, Greece.


Introduction: Women with non-metastatic breast cancer form a distinct subpopulation in which calcium homeostasis in response to treatment with denosumab has not been extensively investigated.

Methods: Female patients with osteoporosis, who were eligible for treatment with denosumab, were prospectively enrolled (2011–2012) and divided into two groups; Group A consisting of patients with either no history or benign diseases non affecting bone metabolism (n=24 controls) and Group B patients with non-metastatic breast cancer (n=18). Documentation of renal impairment, disorders of parathyroid function or the presence of bone metastases served as exclusion criteria. All patients were administered a single-dose of denosumab under standard calcium and vitamin D supplementation. Serum calcium, phosphorus, parathyroid hormone (iPTH) and 24 h urine calcium were measured at days 0, 7 and 180. Primary outcomes were the development of hypocalcaemia and secondary hyperparathyroidism.

Results: At baseline, groups were comparable in age, calcium and iPTH levels. No events of hypocalcaemia were recorded. Overall, incidence of secondary hyperparathyroidism was found to be 45.5% one week after administration of denosumab. Interestingly, at day 180 incidence of secondary hyperparathyroidism was higher in Group B in contrast to the pattern recorded in controls, although not reaching statistical significance. At day 7, iPTH was found to be significantly higher only in controls (Wilcoxon Signed Rank test: P=0.013) compared to group-specific baseline values. At day 180, borderline increase in iPTH of Group B was noted (P=0.08), whereas iPTH returned to baseline in controls.

Discussion: A pattern of delayed development of secondary hyperparathyroidism might be present in patients with non-metastatic breast cancer. It could be extrapolated that this finding might be associated with a partial functional defect in calcium sensing receptor, which has recently been implicated in the pathogenesis of breast cancer. The findings warrant further investigation.